This 2022 protocol, published in Contemporary Clinical Trials, outlines a planned double-blind, placebo-controlled randomized clinical trial to assess the efficacy of oral naltrexone in treating adolescent eating disorders, specifically anorexia nervosa and bulimia nervosa. The study aims to enroll adolescents aged 12–21 who exhibit binge/purge behaviors, administering 50 mg of
